Orchard Therapeutics Plc (NASDAQ: ORTX)
Orchard Therapeutics Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Orchard Therapeutics Plc Company Info
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.
News & Analysis
Why Orchard Therapeutics Stock Is Soaring Today
A buyout offer is fueling a rise in the company's shares today.
Why Orchard Therapeutics Stock Is Jumping Today
The company released some promising data from a pair of proof-of-concept studies.
Got $1,000? Invest in These 2 Rare Disease Stocks
These companies are devoted to helping patients who don't have any other options.
Why Orchard Therapeutics Stock Is Soaring Today
No news is good news for this biotech company.
Why Box, Luckin Coffee, and Orchard Therapeutics Slumped Today
Find out why these stocks were among the few to lose ground on a winning day for the market.
Valuation
Earnings Transcripts
Orchard Therapeutics (ORTX) Q2 2020 Earnings Call Transcript
ORTX earnings call for the period ending June 30, 2020.
Orchard Therapeutics (ORTX) Q1 2020 Earnings Call Transcript
ORTX earnings call for the period ending March 31, 2020.
Orchard Therapeutics (ORTX) Q4 2019 Earnings Call Transcript
ORTX earnings call for the period ending December 30, 2019.
Orchard Therapeutics (ORTX) Q3 2019 Earnings Call Transcript
ORTX earnings call for the period ending September 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.